Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

1.6K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.6K
Inflammation01:38

Inflammation

61.1K
Overview
61.1K
Inflammatory Response01:28

Inflammatory Response

15.6K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pancreatic Stone Protein as an Early Predictor of Adverse Events in Patients with Infection Presenting to the Emergency Department: A Pilot Study.

Journal of personalized medicine·2026
Same author

Hanta on the Hondius - public health and bioethical perspectives of the recent <i>Andes</i> hantavirus cruise ship outbreak.

New microbes and new infections·2026
Same author

The impact of colistin minimum inhibitory concentration on clinical failure and mortality: insights from the OVERCOME trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo and Uganda: rapid assessment from the European Society of Clinical Microbiology and Infectious Diseases Emerging Infections Subcommittee.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Avian Influenza in Humans: Virology, Transmission, and Clinical Priorities.

QJM : monthly journal of the Association of Physicians·2026

Related Experiment Video

Updated: Dec 23, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.7K

COVID-19: lambda interferon against viral load and hyperinflammation.

Evangelos Andreakos1,2, Sotirios Tsiodras3,4

  • 1Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

EMBO Molecular Medicine
|April 26, 2020
PubMed
Summary
This summary is machine-generated.

Interferon-lambda (IFNλ) shows promise for treating COVID-19 by reducing viral load and inflammation. This approach could prevent severe outcomes like pneumonia and ARDS.

Keywords:
COVID-19cytokine stormhyperinflammationinterferonviral infection

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.7K
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

12.3K

Related Experiment Videos

Last Updated: Dec 23, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.7K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.7K
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

12.3K

Area of Science:

  • Immunology
  • Virology
  • Respiratory Medicine

Background:

  • COVID-19 pandemic caused by SARS-CoV-2 has led to significant mortality.
  • Effective therapeutics are crucial to combat the virus and reduce deaths.
  • Type I interferons (IFNs) are involved in antiviral responses, but their role in severe COVID-19 is complex.

Purpose of the Study:

  • To evaluate interferon-lambda (IFNλ) as a potential therapeutic agent for COVID-19.
  • To explore the role of IFNλ in respiratory tract antiviral immunity.
  • To investigate the impact of SARS-CoV-2 on IFNλ induction and its consequences.

Main Methods:

  • Review of existing literature on interferons and COVID-19.
  • Analysis of the unique properties of IFNλ compared to type I IFNs.
  • Discussion of potential therapeutic strategies and safety considerations for IFNλ.

Main Results:

  • SARS-CoV-2 may suppress IFNλ production, leading to a detrimental type I IFN response.
  • This impaired IFNλ response can result in hyperinflammation and severe COVID-19.
  • IFNλ plays a critical role in balancing antiviral immunity and minimizing host tissue damage.

Conclusions:

  • Interferon-lambda (IFNλ) is a promising therapeutic candidate for COVID-19.
  • IFNλ treatment could simultaneously reduce viral presence and mitigate hyperinflammation.
  • This could prevent severe respiratory complications such as pneumonia and ARDS.